Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 301

Sort by

Sort Order Select

Journal Articles

Mechanisms and Therapeutic Strategies to Reverse TET2 Mutant Clonal Hematopoiesis and the Risk of MDS, AML, and Atherosclerotic Cardiovascular Disease

Nicole Prutsch, Amélie Vromman, Brittaney Leeper, Mengyu Chen, Shuning He, Siyang Ren, Christopher J. Walker, Mark W. Zimmerman, Mariana Janini Gomes, Eduardo J. Folco, Philipp J. Rauch, Prafulla C. Gokhale, Brian J. Abraham, Donna S. Neuberg, Benjamin L. Ebert, Peter Libby, A. Thomas Look

Blood (2023) 142 (Supplement 1): 937.

https://doi.org/10.1182/blood-2023-181149

Published: 2023

Journal Articles

Digital Ischemia Associated with Profound Anemia: A Concerning Consequence of Treatment without Transfusions

Jessica A. Thomas, Kathleen Humkey, Ashley Dean, Jay Mehta, George Negrea

Blood (2022) 140 (Supplement 1): 11060–11061.

https://doi.org/10.1182/blood-2022-167842

Published: 2022

Journal Articles

Evaluate Dynamics of IL-6 Release during Step-up Dosing of Subcutaneous Administration of Odronextamab Via a Quantitative Systems Pharmacology Modeling Approach

Masood Khaksar Toroghi, Min Zhu, Srikanth R. Ambati, Hesham Mohamed, Aafia Chaudhry, Hong Yan, John D. Davis, A. Thomas DiCioccio

Blood (2022) 140 (Supplement 1): 11912–11913.

https://doi.org/10.1182/blood-2022-158413

Published: 2022

Journal Articles

Early Treatment with Ofatumumab in Patients with High-Risk CLL

Sai Prasad Desikan, Michael J. Keating, Alessandra Ferrajoli, Nitin Jain, Maro Ohanian, Naveen Pemmaraju, Courtney D. DiNardo, Marina Konopleva, Tapan M. Kadia, Susan O'Brien, Zeev E. Estrov, Deborah A Thomas, Jan A. Burger, Philip A. Thompson, William G. Wierda

Blood (2022) 140 (Supplement 1): 9876–9878.

https://doi.org/10.1182/blood-2022-167284

Published: 2022

Journal Articles

The Hematopoietic Transcription Factor GATA3 Is the Main Activator of Enhancer-Mediated Activation of Oncogenic TAL1 in T-ALL

Joana R Costa, David O'Connor, Nurkaiyisah Anuar, Sunniyat Rahman, Nivedita Singh, Zhaodong China, Tanya Rapoz-D'Silva, Yang Li, Kent Fung, Sara Hyseni, Stephen Henderson, George Morrow, Yanping Guo, Javier Herrero, Richard Jenner, Dennis Keppei, A. Thomas Look, Marc R. Mansour

Blood (2022) 140 (Supplement 1): 3046–3047.

https://doi.org/10.1182/blood-2022-166396

Published: 2022

Journal Articles

A Quantitative Systems Pharmacology Modeling Framework for Evaluation of Cytokine Release Mediated By Intravenous Odronextamab Monotherapy in Patients with B-Cell Non-Hodgkin Lymphoma

Masood Khaksar Toroghi, Min Zhu, Jurriaan Brouwer-Visser, Srikanth R. Ambati, Hesham Mohamed, Aafia Chaudhry, John D. Davis, A. Thomas DiCioccio

Blood (2022) 140 (Supplement 1): 11930–11931.

https://doi.org/10.1182/blood-2022-158412

Published: 2022

Journal Articles

A Rare Case of Spontaneous Tumor Lysis Syndrome As a Consequence of Forgone Treatment in Multiple Myeloma

Kathleen Humkey, Jessica A Thomas, Ashley Dean

Blood (2022) 140 (Supplement 1): 12563.

https://doi.org/10.1182/blood-2022-167851

Published: 2022

Journal Articles

Endothelial MEKK3-KLF2/4 signaling integrates inflammatory and hemodynamic signals during definitive hematopoiesis

Yiqing Yang, Melanie Mumau, Joanna Tober, Qin Zhu, Laura Bennett, Courtney Hong, Derek Sung, Thomas Keller, Yasin Uzun, Peng Gao, Swapnil Shewale, Mei Chen, Jisheng Yang, Xiaowen Chen, Steven A. Thomas, Kai Tan, Nancy A. Speck, Mark L. Kahn

Blood (2022) 139 (19): 2942–2957.

https://doi.org/10.1182/blood.2021013934

Published: 2022

Includes: Supplemental data

Journal Articles

Pathogen Reduced Cryoprecipitate and Fibrinogen Concentrate Have Delayed Resuscitation of Simulated Dilutional Coagulopathy in a Microfluidic Model of Bleeding When Compared to Cryoprecipitate

Kimberly A. Thomas, Philip C. Spinella, Susan M. Shea

Blood (2021) 138 (Supplement 1): 3248.

https://doi.org/10.1182/blood-2021-154184

Published: 2021

Journal Articles

Donor and Storage Duration Impact Cold-Stored Platelet Function More Than Handling Protocols

Susan M. Shea, Philip C. Spinella, Kimberly A. Thomas

Blood (2021) 138 (Supplement 1): 3249.

https://doi.org/10.1182/blood-2021-154408

Published: 2021

Journal Articles

Safety Profile of Maintenance Obinutuzumab in Patients with Primary CNS Lymphoma in Complete Response

Nancy D. Doolittle, Prakash Ambady, David M. Peereboom, Douglas E. Ney, Larry Junck, Yoshie Umemura, Roy Ervin Strowd III, Glenn J. Lesser, David Schiff, Camilo E. Fadul, Michael Glantz, MD PhD, Erin M. Dunbar, Peter Barth, Edward Pan, Alissa A. Thomas, Rongwei Fu, Edward A. Neuwelt

Blood (2020) 136 (Supplement 1): 12.

https://doi.org/10.1182/blood-2020-134457

Published: 2020

Journal Articles

Targeting T-ALL Cells with Potent Activators of the PP2A Protein Phosphatase Tumor Suppressor

Ken Morita, MD PhD, Shuning He, PhD, Radosław P. Nowak, PhD, Jinhua Wang, PhD, Nathanael Gray, PhD, Eric S. Fischer, PhD, A. Thomas Look, MD

Blood (2019) 134 (Supplement_1): 406.

https://doi.org/10.1182/blood-2019-123573

Published: 2019

Journal Articles

Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma

Blood (2019) 133 (5): 436–445.

https://doi.org/10.1182/blood-2018-09-875732

Published: 2019

Includes: Supplemental data

Journal Articles

Phase I Study of the Selinexor in Relapsed/Refractory Childhood Acute Leukemia

Andrew E. Place, MD PhD, Traci M. Blonquist, MS, Elliot Stieglitz, MD, Todd M Cooper, DO, Lia Gore, MD, Richard Aplenc, MD PhD, Mignon L. Loh, MD, Melinda Pauly, MD, Rachel E. Rau, MD, Michael J. Burke, MD, Julia Etchin, PhD, A. Thomas Look, MD, Maria Luisa Sulis, MD, Lewis B. Silverman, MD

Blood (2018) 132 (Supplement 1): 1405.

https://doi.org/10.1182/blood-2018-99-116689

Published: 2018

Journal Articles

Phase II Study of Hyper-Cmad with Liposomal Vincristine (Marqibo) for Patients with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

Koji Sasaki, MD, Elias J. Jabbour, MD, Maria Khouri, Deborah A Thomas, MD, Guillermo Garcia-Manero, MD, Farhad Ravandi, MBBS, Gautam Borthakur, MD, Nicholas J Short, MD, Ghayas C. Issa, MD, Tapan Kadia, MD, Emily Jones, Rebecca Garris, Msc, Jorge E. Cortes, MD, Susan M. O'Brien, MD, Hagop M. Kantarjian, MD

Blood (2017) 130 (Supplement 1): 2554.

https://doi.org/10.1182/blood.V130.Suppl_1.2554.2554

Published: 2017

Journal Articles

Updated Results of the Phase II Trial of Inotuzumab Ozogamicin (INO) Combined with Mini-Hyper-CVD As Salvage Therapy for Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Blood (2017) 130 (Supplement 1): 2597.

https://doi.org/10.1182/blood.V130.Suppl_1.2597.2597

Published: 2017

Journal Articles

Hyper-CVAD Plus Ofatumumab As Frontline Therapy in CD20+ Acute Lymphoblastic Leukemia: Updated Results of a Phase II Trial

Blood (2017) 130 (Supplement 1): 3876.

https://doi.org/10.1182/blood.V130.Suppl_1.3876.3876

Published: 2017

Journal Articles

A Phase I/II Study of Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) for Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

Blood (2017) 130 (Supplement 1): 2576.

https://doi.org/10.1182/blood.V130.Suppl_1.2576.2576

Published: 2017

Journal Articles

Activation of the LMO2 oncogene through a somatically acquired neomorphic promoter in T-cell acute lymphoblastic leukemia

Blood (2017) 129 (24): 3221–3226.

https://doi.org/10.1182/blood-2016-09-742148

Published: 2017

Includes: Supplemental data

Journal Articles

Frontline Ofatumumab in Combination with Hyper-CVAD for Adult Patients with CD-20 Positive Acute Lymphoblastic Leukemia (ALL): Interim Result of a Phase II Clinical Trial

Blood (2016) 128 (22): 2783.

https://doi.org/10.1182/blood.V128.22.2783.2783

Published: 2016

NARROW

Mechanisms and Therapeutic Strategies to Reverse TET2 Mutant Clonal Hematopoiesis and the Risk of MDS, AML, and Atherosclerotic Cardiovascular Disease

Digital Ischemia Associated with Profound Anemia: A Concerning Consequence of Treatment without Transfusions

Evaluate Dynamics of IL-6 Release during Step-up Dosing of Subcutaneous Administration of Odronextamab Via a Quantitative Systems Pharmacology Modeling Approach

Early Treatment with Ofatumumab in Patients with High-Risk CLL

The Hematopoietic Transcription Factor GATA3 Is the Main Activator of Enhancer-Mediated Activation of Oncogenic TAL1 in T-ALL

A Quantitative Systems Pharmacology Modeling Framework for Evaluation of Cytokine Release Mediated By Intravenous Odronextamab Monotherapy in Patients with B-Cell Non-Hodgkin Lymphoma

A Rare Case of Spontaneous Tumor Lysis Syndrome As a Consequence of Forgone Treatment in Multiple Myeloma

Endothelial MEKK3-KLF2/4 signaling integrates inflammatory and hemodynamic signals during definitive hematopoiesis

Pathogen Reduced Cryoprecipitate and Fibrinogen Concentrate Have Delayed Resuscitation of Simulated Dilutional Coagulopathy in a Microfluidic Model of Bleeding When Compared to Cryoprecipitate

Donor and Storage Duration Impact Cold-Stored Platelet Function More Than Handling Protocols

Safety Profile of Maintenance Obinutuzumab in Patients with Primary CNS Lymphoma in Complete Response

Targeting T-ALL Cells with Potent Activators of the PP2A Protein Phosphatase Tumor Suppressor

Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma

Phase I Study of the Selinexor in Relapsed/Refractory Childhood Acute Leukemia

Phase II Study of Hyper-Cmad with Liposomal Vincristine (Marqibo) for Patients with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

Updated Results of the Phase II Trial of Inotuzumab Ozogamicin (INO) Combined with Mini-Hyper-CVD As Salvage Therapy for Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Hyper-CVAD Plus Ofatumumab As Frontline Therapy in CD20+ Acute Lymphoblastic Leukemia: Updated Results of a Phase II Trial

A Phase I/II Study of Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) for Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

Activation of the LMO2 oncogene through a somatically acquired neomorphic promoter in T-cell acute lymphoblastic leukemia

Frontline Ofatumumab in Combination with Hyper-CVAD for Adult Patients with CD-20 Positive Acute Lymphoblastic Leukemia (ALL): Interim Result of a Phase II Clinical Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only